Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab
© 2017 S. Karger AG, Basel..
Recently, the use of biosimilar infliximab (IFX) in the treatment of inflammatory bowel diseases has become widespread in some European and non-European countries. Data on the efficacy, safety and immunogenicity from real-life cohorts are accumulating. The first reports showed similar outcomes in the induction and maintenance of remission, mucosal healing, safety and immunogenicity profile to the originator IFX. In the present review, we aimed to summarize the existing knowledge on the efficacy, safety and immunogenicity profile of biosimilar IFX reported from real-life cohorts.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Digestive diseases (Basel, Switzerland) - 35(2017), 1-2 vom: 21., Seite 101-106 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vegh, Zsuzsanna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 24.02.2017 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000449089 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM26854574X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM26854574X | ||
| 003 | DE-627 | ||
| 005 | 20231224222843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000449089 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0895.xml |
| 035 | |a (DE-627)NLM26854574X | ||
| 035 | |a (NLM)28147369 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vegh, Zsuzsanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2017 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 S. Karger AG, Basel. | ||
| 520 | |a Recently, the use of biosimilar infliximab (IFX) in the treatment of inflammatory bowel diseases has become widespread in some European and non-European countries. Data on the efficacy, safety and immunogenicity from real-life cohorts are accumulating. The first reports showed similar outcomes in the induction and maintenance of remission, mucosal healing, safety and immunogenicity profile to the originator IFX. In the present review, we aimed to summarize the existing knowledge on the efficacy, safety and immunogenicity profile of biosimilar IFX reported from real-life cohorts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Biosimilar Pharmaceuticals |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 700 | 1 | |a Kurti, Zsuzsanna |e verfasserin |4 aut | |
| 700 | 1 | |a Lakatos, Peter L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive diseases (Basel, Switzerland) |d 1996 |g 35(2017), 1-2 vom: 21., Seite 101-106 |w (DE-627)NLM013004395 |x 1421-9875 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2017 |g number:1-2 |g day:21 |g pages:101-106 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000449089 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2017 |e 1-2 |b 21 |h 101-106 | ||